HAVCR2 and melanoma: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of TIM-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma